UBS’s Novo Nordisk NVO Stock Holding History

UBS’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	$210K	Buy	8,800 +7,600	+633%	+$175K	﹤0.01%	5138
2014 Q2	$28K	Sell	1,200 -26,000	-96%	-$574K	﹤0.01%	7654
2014 Q1	$621K	Sell	27,200 -13,800	-34%	-$294K	﹤0.01%	4000
2013 Q4	$758K	Sell	41,000 -3,000	-7%	-$52.3K	﹤0.01%	3852
2013 Q3	$745K	Buy	44,000 +13,000	+42%	+$219K	﹤0.01%	3690
2013 Q2	$480K	Buy	+31,000	New	+$516K	﹤0.01%	4147

Other funds holding NVO

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

UBS's NVO Position: Q3 2014 in Review

UBS increased its Novo Nordisk (NVO) stake by 8.4% in Q3 2014, buying an estimated $1.78M and bringing the position to 1,002,186 shares worth $23.9M. The position accounts for 0.02% of the portfolio, ranked #854.

UBS first reported a position in NVO in Q2 2013 and has held it in 6 quarters since. 470 funds tracked by Wall St. Rank hold NVO as of Q3 2014.

UBS held 1,002,186 shares of Novo Nordisk worth $23.9M as of Q3 2014.
UBS bought 77,380 Novo Nordisk shares in Q3 2014, an estimated $1.78M.
Novo Nordisk made up 0.02% of UBS's portfolio in Q3 2014, its #854 holding.
UBS first reported a position in Novo Nordisk in Q2 2013 and has held it in 6 quarters since.
470 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.